Interesting study to measure the interaction between change in psychosis and liability to develop motor side effects with antipsychotics using data from 15 clinical trials of INVEGA®, INVEGA SUSTENNA®, and RISPERDAL®. Authors describe their analyses as primarily descriptive with mixed model regression modeling to understand the association between change in psychosis and motor side effects, seemingly unadjusted for other covariates (and no other covariates are listed). However, I would expect these analyses would be stronger if the mixed model regression modeling included adjustment for sociodemographic and/or clinical covariates (that should be pre-specified), particularly if any were known to be associated with likelihood of either success in psychosis treatment or in developing motor side effects.